Photonics West 2021: OCT makes further biomedical breakthroughs
17 Mar 2021
Michael Kaschke outlines the factors driving OCT s continued translation from bench to bedside.
So commented Michael Kaschke, former Chairman of Zeiss for a decade and as of November 2019 Chairman of the KIT Supervisory Board, when he addressed the SPIE Photonics West Digital Forum on the topic of OCT s past success and likely future applications. At the World Ophthalmology Congress in 2009 I was asked what technologies I believed would play a key role in the following decade, said Kaschke. I said that ubiquitous use of OCT was one, along with multifocal lenses, femtosecond lasers in surgery, drug treatment for glaucoma and AMD, and development of accommodating lenses. Judgment on the last one is still out, but the other four predictions all came true.
Lumentum raises Coherent offer to $6.9BN with private equity backing
17 Mar 2021
The bidding war to acquire laser company Coherent shows no sign of abating, with Lumentum responding to II-VIâs latest offer with another increased bid of its own.
Estimated to be worth $6.9Â billion - slightly higher than II-VIâs latest offer - the new Lumentum deal would see $220 in cash and 0.61Â Lumentum shares exchanged for each Coherent share.
Although Coherent has acknowledged receipt of the latest revised offer from Lumentum, the Santa Clara firm says its board of directors will carefully evaluate it before deciding whether to recommend it over the II-VI bid.